A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor